Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Italian biomedical charity Fondazione Telethon, which is focused on rare genetic diseases, revealed it has submitted a ...

Shortly after this publication, Bogdanove struck up a collaboration with Daniel Voytas, a plant geneticist at the University ...

Etanercept and adalimumab are both recommended to be available as routine commissioning treatment options for deficiency of adenosine deaminase type 2 (DADA2) within the criteria set out in these ...

(B) The overall design of DRAM, DRAM mut and Deaminase system. (F) Screening process for DRAM-seq assays and principles for screening high-confidence genes. (G) The pie chart shows the distribution of ...

This month's cover highlights the article Immune cells adapt to confined environments in vivo to optimise nuclear plasticity for migration by Helen Weavers and Tua Karling. The cover features confocal ...

Figure 1 The complex landscape of lncRNAs in viral Infections and immunity. Viruses, being obligatory intracellular pathogens, are dependent on host cell processes such as transcription and ...

This manuscript provides a deep mutational scanning of the deaminase domain of human ADAR2 to provide a comprehensive assessment of amino acids that alter editing activity at a specific adenosine ...